Recent SEC filings
Insider and ownership filing tracker
Form 4 reports insider transactions. Schedule 13D and 13G filings report certain significant ownership positions. 13F reports institutional holdings when filed by an investment manager. Always open the original filing for context.
Company and financial overview
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
Financial performance charts
Annual values from SEC filings. Free cash flow is calculated as operating cash flow less capital expenditures.
Upcoming catalyst timeline
Review the Earnings tab for the expected date and estimates.
8-K
EMA, RSI, MACD, volume, structure, and key levels update after a completed daily candle.
How the research score works
The overall score is a weighted research judgment covering business quality, fundamental strength, growth catalysts, valuation, technical condition, and downside risk. A high score does not eliminate risk, and a low score does not guarantee poor performance.
Company overview
Boston Scientific develops and manufactures medical devices across cardiovascular, endoscopy, urology, and neuromodulation categories, serving hospitals and healthcare providers globally with a broad and continuously expanding product portfolio.
Business model
The company earns revenue from selling medical devices across its diversified categories, with a strong track record of new product innovation and category expansion supporting above average growth relative to typical medical device peers.
Growth drivers
- Continued new product launches across cardiovascular and other categories
- Structural heart device category growth
- International market expansion
- Selective acquisitions supplementing organic innovation
Competitive position
Boston Scientific's consistent innovation track record and diversified device portfolio have supported market share gains across multiple categories, giving it a differentiated growth profile relative to more mature medical device competitors.
Risks
Competition in cardiovascular and other device categories is intense, healthcare capital spending cycles affect hospital purchasing, and litigation risk is inherent to the medical device industry given the nature of implantable products.
Valuation
Boston Scientific trades at a premium multiple typical of high growth medical device companies, reflecting its consistent innovation driven growth relative to the broader device industry.
Final view
Boston Scientific's consistent new product innovation has driven above average growth relative to medical device peers over an extended period. My view is favorable, with continued pipeline execution being the key thing to sustain that growth trajectory.
Overall rating: 79/100
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market data is provided by Finnhub and other third-party sources and may be delayed, incomplete, or inaccurate. The author may hold positions in securities discussed, and opinions may change without notice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.